Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial
Inserm · Délégation Paris 7 · +21 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
815
total citations
- FWCI
- 42.05
- Percentile
- 100%
- References
- 30
Citations per year
Authors
140- VVValérie VilgrainCorresponding
Inserm, Délégation Paris 7, Université Paris Cité, Hôpital Beaujon, Sorbonne Paris Cité, Assistance Publique – Hôpitaux de Paris, Centre de Recherche sur l'Inflammation
- HPHéléna Pereira
Inserm, Assistance Publique – Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Hôpital Européen
- EAEric Assenat
Centre Hospitalier Universitaire de Montpellier, Hôpital Saint Eloi
- BGBoris Guiu
Centre Hospitalier Universitaire de Montpellier, Hôpital Saint Eloi
- ADAlina Diana Ilonca
Centre Hospitalier Universitaire de Montpellier, Hôpital Gui de Chauliac
Topics & keywords
Topics
Keywords
- Sorafenib
- Hepatocellular carcinoma
- Medicine
- Selective internal radiation therapy
- Liver function
- Internal medicine
- Adverse effect
- Clinical endpoint
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.